Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.45USD
21 Jul 2017
Change (% chg)

$-0.13 (-8.23%)
Prev Close
$1.58
Open
$1.59
Day's High
$1.59
Day's Low
$1.42
Volume
924,292
Avg. Vol
404,474
52-wk High
$2.40
52-wk Low
$1.01

ALIM.O

Chart for ALIM.O

About

Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The... (more)

Overall

Beta: 2.20
Market Cap(Mil.): $94.11
Shares Outstanding(Mil.): 64.90
Dividend: --
Yield (%): --

Financials

  ALIM.O Industry Sector
P/E (TTM): -- 11.79 15.85
EPS (TTM): -0.51 -- --
ROI: -76.29 -10.04 -8.31
ROE: -- -9.89 -7.95

BRIEF-Alimera Sciences announces italian patients now being treated with Iluvien

* Alimera Sciences announces italian patients now being treated with Iluvien® Source text for Eikon: Further company coverage:

Jul 12 2017

BRIEF-pSivida- in connection with new collaboration agreement, Alimera forgave $10 mln of co's share of losses associated with commercialization of ILUVIEN

* pSivida - in connection with new collaboration agreement, alimera forgave $10 million of co's share of losses associated with commercialization of ILUVIEN

Jul 10 2017

BRIEF-ALIMERA SCIENCES REPORTS Q1 LOSS PER SHARE $0.10

* ALIMERA SCIENCES REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

May 08 2017

BRIEF-Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain

* Alimera Sciences signs agreement for exclusive distributor of Iluvien in Spain

Mar 13 2017

BRIEF-Alimera Sciences Q4 adjusted non-gaap loss per share $0.10

* Alimera sciences reports record fourth quarter and full year 2016 financial results

Mar 01 2017

BRIEF-Alimera Sciences and Knight Therapeutics file new drug submission for iluvien in Canada

* Alimera Sciences and Knight Therapeutics announce filing of new drug submission for iluvien in Canada

Feb 22 2017

BRIEF-Alimera Sciences says its unit Alimera Sciences Ltd received pricing, reimbursement decree for ILUVIEN on Jan. 11

* Alimera Sciences-unit Alimera Sciences received pricing and reimbursement decree for ILUVIEN from Agenzia Italiana Del Farmaco (AIFA) on Jan 11, 2017 Source text for Eikon: Further company coverage:

Feb 06 2017

Competitors

Earnings vs. Estimates